CTAP (TFA)

CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].

Product Specifications

UNSPSC

12352209

Target

Opioid Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ctap-tfa.html

Purity

99.60

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H](CSSC(C)([C@H](NC([C@](NC([C@@H](NC1=O)CCCNC(N)=N)=O)([H])[C@H](O)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.OC(C(F)(F)F)=O.[x]

Molecular Formula

C51H69N13O11S2.xC2HF3O2

Molecular Weight

1104.30 (free base)

References & Citations

[1]Mitchell J Bartlett, et al. Highly-selective µ-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes|[2]Abbruscato TJ, et al. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther. 1997 Jan;280 (1) :402-9.